(Total Views: 416)
Posted On: 06/30/2025 7:09:41 PM
Post# of 154811
Re: HouseofCards #154684
Well, taking a look at this chart which I obtained from
https://www.reddit.com/r/Livimmune/comments/1...th_immune/
https://www.researchgate.net/publication/3714...-types.png
ORR sits near the bottom.
From IMy Post on ORR
I'm thinking, even if we doubled it to 14% and got it just above the diagonal line dividing the Cold Tumors from the Hot Tumors, then we should get Accelerated Approval on the surrogate biomarker of ORR.
From the write up, I'm thinking we hit an ORR of 30%
Still can't put the image on directly...
https://www.reddit.com/r/Livimmune/comments/1...th_immune/
https://www.researchgate.net/publication/3714...-types.png
ORR sits near the bottom.
From IMy Post on ORR
Quote:
" The SUNLIGHT Phase 3 trial, which evaluated the combination of Trifluridine/Tipiracil with Bevacizumab in patients with metastatic colorectal cancer, reported an overall response rate (ORR) of 6.9% for the combination therapy . This response rate includes partial responses observed in patients, and although it was modest, the combination therapy still demonstrated significant improvements in overall survival and progression-free survival compared to Trifluridine/Tipiracil alone "
I'm thinking, even if we doubled it to 14% and got it just above the diagonal line dividing the Cold Tumors from the Hot Tumors, then we should get Accelerated Approval on the surrogate biomarker of ORR.
From the write up, I'm thinking we hit an ORR of 30%
Still can't put the image on directly...
(6)
(0)
